Late-stage immuno-oncology company, OncoSec Medical Incorporated, is honing in on the development and commercialization of intra-tumoral DNA-based therapeutics aimed to boost anti-tumor immune responses for cancer treatment. The firm's product pipeline includes KEYNOTE-695, currently undergoing Phase 2 trials for advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, in the midst of a Phase 1 clinical trial for COVID-19 treatment; and TAVO + epacadostat + pembrolizumab, which is undergoing Phase 1 clinical trial for squamous cell carcinoma head and neck cancer treatment. Additionally, its pipeline comprises TAVO + nivolumab, which is still in Phase 2 clinical trial for breast cancer treatment; TAVO + CXCL9 for treating solid tumors; and OMS-100 and OMS-102, subject to Phase 2 clinical trials for the treatment of metastatic melanoma. OncoSec Medical has entered into clinical trial collaborations with Merck & Co., Inc. and its subsidiary for KEYNOTE-695 and KEYNOTE-890, and with Duke University's Center for Applied Therapeutics for assessing TAVO in combination or sequentially with a HER2-plasmid vaccine. Once named NetVentory Solutions Inc., OncoSec Medical was renamed in 2011 and is headquartered in New Jersey's Pennington.
OncoSec Medical Incorporated's ticker is ONCS
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 11-50 employees working at OncoSec Medical Incorporated
It is https://oncosec.com/
OncoSec Medical Incorporated is in the Healthcare sector
OncoSec Medical Incorporated is in the Biotechnology industry
The following five companies are OncoSec Medical Incorporated's industry peers: